



Supplementary Fig. 2. Telmisartan increases p-Akt-Ser⁴⁷³ and p-GSK3β-Ser⁹ in hyperglycemic HepG2 cells. HepG2 cells were treated with various doses of telmisartan (0, 10, 20, or 40 M) for 24 h in the presence of 25 mM D-glucose and then with 100 nM insulin for further 10 min. Western blot analyses were performed as described in Fig. 1. Blots represent at least four experiments. Bar graphs show mean fold alterations above/below control (\pm SD). Differences were statistically significant at ^{a)} $p < 0.05$, ^{b)} $p < 0.01$. GSK3β, glycogen synthase kinase-3β.